Home Galena Biopharma Inc (GALE) Price Target Lowered to $6.00 at Roth Capital
 

Keywords :   


Galena Biopharma Inc (GALE) Price Target Lowered to $6.00 at Roth Capital

2016-01-01 17:14:30| Biotech - Topix.net

The brokerage presently has a "buy" rating on the biotechnology company's stock. Roth Capital's price objective indicates a potential upside of 308.16% from the company's current price.

Tags: price capital target gale

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
25.06Royal Mail buyer to make offer for all staff shares
25.06Hybrid Software wins FLAG Vendor Partner of the Year award
25.06Hospeco Purchases Nuance Solutions
25.06Atlantic Tropical Weather Outlook
25.06DNA Genetics opens new commercial sow research farm
25.06Eastern North Pacific Tropical Weather Outlook
25.06Briolf Group to Invest $30 Million in Its First US Production Plant
25.06IDENTCO rebrands TTL200 Series to DuraWrap and DuraFlag
More »